DHEA Peptide vs Pasireotide
Overview
DHEA Peptide and Pasireotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares DHEA Peptide and Pasireotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| DHEA Peptide | Pasireotide | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | Research use only | FDA approved |
| Typical dosage | 25-50 mg | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) |
| Frequency | daily | Twice daily (SC formulation) or every 4 weeks (LAR formulation) |
| Reported benefits | Hormone balance, energy, anti-aging | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism |
| Reported side effects | Possible acne, hormone fluctuations | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) |
Key differences
Primary use. DHEA Peptide is categorised under Hormonal, while Pasireotide falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. DHEA Peptide: not FDA-approved; treated as a research compound. Pasireotide: FDA-approved.
Dosing. DHEA Peptide is typically dosed at 25-50 mg (daily). Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)).
Can you stack them?
Some protocols combine peptides, but stacking DHEA Peptide and Pasireotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between DHEA Peptide and Pasireotide?
- DHEA Peptide and Pasireotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. DHEA Peptide is not FDA-approved; generally classified as a research compound, whereas Pasireotide is FDA-approved for one or more indications.
- What is DHEA Peptide used for?
- Hormone precursor support.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- Can you take DHEA Peptide and Pasireotide together?
- Some users combine peptides within a single protocol, but stacking DHEA Peptide and Pasireotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is DHEA Peptide or Pasireotide FDA-approved?
- DHEA Peptide is not FDA-approved; generally classified as a research compound. Pasireotide is FDA-approved for one or more indications.
Read the full articles
- DHEA Peptide — full monograph: mechanism, research, dosing & references
- Pasireotide — full monograph: mechanism, research, dosing & references